Imre Kovesdi
Directeur Technique/Scientifique/R&D chez DNAtrix, Inc.
Profil
Imre Kovesdi is currently the Senior Vice President-Research at DNAtrix, Inc. He was previously the Chairman & Chief Executive Officer at Vectorlogics, Inc. from 2005 to 2012.
He also held the position of Chief Scientific Officer at GenVec, Inc. Dr. Kovesdi received his undergraduate degree from the University of British Columbia and his doctorate from Simon Fraser University.
Postes actifs de Imre Kovesdi
| Sociétés | Poste | Début |
|---|---|---|
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Directeur Technique/Scientifique/R&D | 23/10/2012 |
Anciens postes connus de Imre Kovesdi
| Sociétés | Poste | Fin |
|---|---|---|
Vectorlogics, Inc.
 Vectorlogics, Inc. BiotechnologyHealth Technology Vectorlogics, Inc. develops and commercialized vaccines for virus based cancer therapies and viral liver diseases. The company was founded by David T. Curiel in 1998 and is headquartered in Birmingham, AL. | Directeur Général | 01/01/2012 |
| GENVEC INC | Directeur Technique/Scientifique/R&D | - |
Formation de Imre Kovesdi
| Simon Fraser University | Doctorate Degree |
| University of British Columbia | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Vectorlogics, Inc.
Vectorlogics, Inc. BiotechnologyHealth Technology Vectorlogics, Inc. develops and commercialized vaccines for virus based cancer therapies and viral liver diseases. The company was founded by David T. Curiel in 1998 and is headquartered in Birmingham, AL. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Technology |
